Literature DB >> 9926544

Six deaths linked to concomitant use of buprenorphine and benzodiazepines.

M Reynaud1, G Petit, D Potard, P Courty.   

Abstract

AIMS: Buprenorphine at high dosage became available in 1996 for substitution treatment in France. This drug is considered particularly safe and has become widely available in general medical practice. We investigated the possible implication of a buprenorphine-benzodiazepine association in six deaths of known abusers.
DESIGN: Full investigation of cause of death was conducted for six drug abusers.
SETTING: The deaths occurred in two regions of France (Auvergne and Lorraine). Assays were carried out by the Institut de Medecine Legale at Strasbourg, France, one of the few French laboratories equipped to assay buprenorphine. MEASUREMENT: First, the blood and urine underwent triple exhaustive screening. Secondly, buprenorphine and norbuprenorphine were analysed in all the autopsy samples by HPLC/MS.
FINDINGS: Benzodiazepine-buprenorphine associations were found in every case; no other substances that could account for the death were found. The tissue concentrations were markedly higher than the blood levels.
CONCLUSION: If the number of deaths linked to such drug misuse proves high, it may be necessary to review how buprenorphine is dispensed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9926544     DOI: 10.1046/j.1360-0443.1998.93913859.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  33 in total

1.  The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: prevalence of co-occurrence in a national sample.

Authors:  Sean Esteban McCabe; James A Cranford; Carol J Boyd
Journal:  Drug Alcohol Depend       Date:  2006-04-18       Impact factor: 4.492

2.  Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting.

Authors:  Devin Tucker; Kanna Hayashi; M-J Milloy; Seonaid Nolan; Huiru Dong; Thomas Kerr; Evan Wood
Journal:  Addict Behav       Date:  2015-10-09       Impact factor: 3.913

3.  Correlates of nonmedical use of prescription benzodiazepine anxiolytics: results from a national survey of U.S. college students.

Authors:  Sean Esteban McCabe
Journal:  Drug Alcohol Depend       Date:  2005-07       Impact factor: 4.492

Review 4.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Prevalence of adverse drug combinations in a large post-mortem toxicology database.

Authors:  Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2008-06-27       Impact factor: 2.686

6.  Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.

Authors:  Marc J Fishman; Li-Tzy Wu; George E Woody
Journal:  Am J Psychiatry       Date:  2011-07       Impact factor: 18.112

7.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

8.  Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D.

Authors:  Walid F Gellad; Xinhua Zhao; Carolyn T Thorpe; Joshua M Thorpe; Florentina E Sileanu; John P Cashy; Maria Mor; Jennifer A Hale; Thomas Radomski; Leslie R M Hausmann; Michael J Fine; Chester B Good
Journal:  Subst Abus       Date:  2016-12-07       Impact factor: 3.716

9.  Medical use, illicit use, and diversion of abusable prescription drugs.

Authors:  Sean Esteban McCabe; Christian J Teter; Carol J Boyd
Journal:  J Am Coll Health       Date:  2006 Mar-Apr

Review 10.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.